The AR clearly represents the Achilles’ heel of prostate cancer yet the current primary treatment involving androgen antagonists has limitations and also leads to expression of an alternative AR-driven transcriptome with variable PCa outcomes [37]. This evidence concerns the gene AR and prostate cancer.